Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Public ClinicalTrials.gov record NCT01727076. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Study identification
- NCT ID
- NCT01727076
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Carcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Renal Cell Carcinoma
- Recurrent Skin Carcinoma
- Stage III Renal Cell Cancer
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Renal Cell Cancer
Interventions
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Recombinant Human Interleukin-15 Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 19 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2013
- Primary completion
- Jun 29, 2016
- Completion
- Jun 29, 2016
- Last update posted
- Sep 14, 2017
2013 – 2016
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Institute Palo Alto | Palo Alto | California | 94304 | — |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
| University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01727076, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2017 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01727076 live on ClinicalTrials.gov.